Identifying a Novel Diagnostic and Therapeutic Target for Metastatic Breast Cancer. Michele Vitolo, Ph.D.
|
|
- Cuthbert Griffith
- 7 years ago
- Views:
Transcription
1 Identifying a Novel Diagnostic and Therapeutic Target for Metastatic Breast Cancer Michele Vitolo, Ph.D.
2 Clinical Problem: Breast Cancer #1 cancer (US women) Metastatic disease: 5-year survival 25% #2 cause of cancer-related death
3 Challenges of Metastasis Diagnostic Limited radiologic detection of early spreading Therapeutic Systemic agents have limited long-term success CTCs Key: Circulating Tumor Cells (CTCs)
4 Overview Tubulin-based membrane protrusions (microtentacles) observed in detached cells Role for microtentacles in cancer progression and metastasis α-tubulin acetylation, microtentacle formation, adhesion, and invasive migration
5 Response of epithelial cells to detachment Membrane protrusions Frame / 1 sec.
6 Cytoskeletal support of membrane protrusions - Microtentacles Rebecca Whipple et al., Exp. Cell Res. 313: (2007). Control LA Inhibit actin polymerization Destroys Filopodia and invadopodia Phase Contrast -tubulin Actin
7 Microtentacles increase in invasive/metastatic breast tumor cell lines Rebecca Whipple et al., Cancer Research 68: (2008).
8 Example of a Patients CTC
9 Microtentacles promote binding to adjacent cells
10 Confocal imaging of live tumor cell attachment to endothelial cells
11 Confocal imaging of CTCs isolated from human breast cancer patients
12 Primary tumor Even small tumors shed millions of cells into bloodstream. Death from fragmentation Target microtentacles Fates of circulating cells? Death from apoptosis [1] ADHESION Microtentacles [2] EXTRAVASATION Actin-dependent Metastatic tumor
13 Microtubule stabilization and metastasis Matrone et al., Cancer Research 70(20): 7737:7741 (2010).
14 αtubulin Acetylation Acetylase ( TAT1) Deacetylases (HDAC6, SIRT2)
15 Metastatic breast tumor cell lines have high acetylation of α-tubulin Amanda E. Boggs et al. Cancer Res 2015;75: by American Association for Cancer Research
16 Metastatic breast tumor cell lines have high acetylation of α-tubulin that is enriched in more numerous McTNs. Amanda E. Boggs et al. Cancer Res 2015;75: by American Association for Cancer Research
17 Reduction of αtubulin Acetylation K40R acetylation resistant: ( Acetyl-Tub)
18 K40R α-tubulin mutant expression 2015 by American Association for Cancer Research Amanda E. Boggs et al. Cancer Res 2015;75:
19 K40R α-tubulin mutant decreases acetylation and McTN frequency Amanda E. Boggs et al. Cancer Res 2015;75: by American Association for Cancer Research
20 Increase in αtubulin Acetylation Acetylase ( TAT1) αtat overexpression: ( Acetyl-Tub)
21 Overexpression of αtat1 increases tubulin acetylation Amanda E. Boggs et al. Cancer Res 2015;75: by American Association for Cancer Research
22 αtat1 significantly increases α-tubulin acetylation and McTNs Amanda E. Boggs et al. Cancer Res 2015;75: by American Association for Cancer Research
23 α-tubulin acetylation significantly affects reattachment rates of suspended breast tumor cells 2015 by American Association for Cancer Research Amanda E. Boggs et al. Cancer Res 2015;75:
24 Chemotactic movement of breast tumor cells is affected by reducing acetylated α-tubulin Amanda E. Boggs et al. Cancer Res 2015;75: by American Association for Cancer Research
25 Chemotactic movement of breast tumor cells is affected by reducing acetylated α-tubulin Amanda E. Boggs et al. Cancer Res 2015;75: by American Association for Cancer Research
26 Acetylated α-tubulin is detected in patient primary and matched metastatic tumors 2015 by American Association for Cancer Research Amanda E. Boggs et al. Cancer Res 2015;75:
27 High acetylation of α-tubulin in patient primary tumors is linked to the basallike subtype and an increased risk of disease progression and death Amanda E. Boggs et al. Cancer Res 2015;75: by American Association for Cancer Research
28 Conclusions 1. Significant association between breast cancer cell lines and high acetylation of - tubulin that extends along the length of McTNs. 2. Mutation of the specific lysine 40 acetylation site on -tubulin as well as enzymatic modulation of this PTM has a significant impact on McTNs frequency and cancer cell attachment. -tubulin is necessary for migration. 4. Match primary and metastatic tissue arrays show tubulin acetylation is maintained or increased in nodal metastases. 5. Large proteomics study (390 patients) link high tubulin acetylation to the aggressive basal-like subype. 6. A trend of increased risk of disease progression and death when -tubulin is high in a patient s primary tumor.
29 Department of Physiology Stuart Martin Rebecca Whipple-Bettes Agnes Cheung Eric Balzer Jennifer Yoon Ed Cho Mike Matrone Keyata Thompson Monica Charpentier Amanda Boggs Lek Bhandary Kristi Chakrabarti Lindsay Hessler Olga Ioffe Kim Tuttle Toshi Yoneda (MD Anderson) Gordon Mills (MD Anderson) Jing Yang (UCSD) Wolfgang Losert (UM-College Park) Carol Otey (UNC-Chapel Hill) State of Maryland Cigarette Restitution Fund K01-CA Howard Temin Career Award (NCI) UMB Independent New Investigator Award (Dean s Office) Department of Defense Breast Cancer Concept Award S10-RR (NCRR, Xenogen) R01-CA (NCI) Department of Defense Breast Cancer Idea Award FAMRI Clinical Innovator Award DOD Breast Cancer Predoctoral (Balzer) DOD Breast Cancer Predoctoral (Cho) Maryland Stem Cell Research Foundation Susan G. Komen for the Cure Department of Defense Breast Cancer Era of Hope Scholar Award R01-CA (NCI) K01-CA (NCI)
30 Publications including data from the Xcelligence RTCA DP 1. Matrone, M.A., Whipple, R.A., Thompson, K., Cho, E.H., Vitolo, M.I., Balzer, E.M., Yoon, J.R., Ioffe, O.B., Tuttle, K.C., Tan, M. and Martin, S.S. (2010) Metastatic breast tumors express increased tau, which promotes microtentacle formation and the reattachment of detached breast tumor cells. Oncogene. Jun 3;29(22): Whipple, R.A., Cho, E.H., Balzer, E.M., Matrone, M.A., Vitolo, M.I., Yoon, J.R., Ioffe, O.B., Tuttle, K.C., Yang, J. and Martin, S.S. (2010) Epithelial-to-mesenchymal transition promotes tubulin detyrosination and microtentacles that enhance endothelial engagement. Cancer Res. Oct 15;70(20): Yoon, J.R., Whipple, R.A., Balzer, E.M., Cho, E.H., Matrone, M.A. and Martin, S.S. (2011). Local anesthetics inhibit kinesin motility and microtentacle protrusions of human epithelial and breast tumor cells. Breast Cancer Res.Treat. Oct;129(3): Vitolo MI, Boggs AE, Whipple RA, Yoon JR, Thompson K, Matrone MA, Cho EH, Balzer EM, Martin SS. (2013) Loss of PTEN induces microtentacles through PI3K-independent activation of cofilin. Oncogene. Apr 25;32(17): Whipple RA, Vitolo MI, Boggs AE, Charpentier MS, Thompson K, Martin SS. (2013) Parthenolide and costunolide reduce microtentacles and tumor cell attachment by selectively targeting detyrosinated tubulin independent from NF-κB inhibition. Breast Cancer Res.15(5):R Charpentier MS, Whipple RA, Vitolo MI, Boggs AE, Slovic J, Thompson KN, Bhandary L, Martin SS. (2014) Curcumin targets breast cancer stem-like cells with microtentacles that persist in mammospheres and promote reattachment. Cancer Res. Feb 15;74(4): Perry NA, Vitolo MI, Martin SS, Kontrogianni-Konstantopoulos A. (2014) Loss of the obscurin-rhogef downregulates RhoA signaling and increases microtentacle formation and attachment of breast epithelial cells. Oncotarget. Sep 30;5(18): Boggs AE, Vitolo MI, Whipple RA, Charpentier MS, Goloubeva OG, Ioffe OB, Tuttle KC, Slovic J, Lu Y, Mills GB, Martin SS. (2015) α-tubulin acetylation elevated in metastatic and basal-like breast cancer cells promotes microtentacle formation, adhesion, and invasive migration. Cancer Res Jan 1;75(1): Bhandary L, Whipple RA, Vitolo MI, Charpentier MS, Boggs AE, Chakrabarti KR, Thompson KN, Martin SS. (2015) ROCK inhibition promotes microtentacles that enhance reattachment of breast cancer cells. Oncotarget. Mar 20;6(8):
Department of BioScience Technology Chung Yuan Christian University 2015/08/13
Department of BioScience Technology Chung Yuan Christian University 2015/08/13 Cancer Cells Cancer, the 1st leading cause of death, is an example of a disease that arises from abnormalities in cell function
More informationWhat is Cancer? Cancer is a genetic disease: Cancer typically involves a change in gene expression/function:
Cancer is a genetic disease: Inherited cancer Sporadic cancer What is Cancer? Cancer typically involves a change in gene expression/function: Qualitative change Quantitative change Any cancer causing genetic
More informationFuture Directions in Cancer Research What does is mean for medical physicists and AAPM?
Future Directions in Cancer Research What does is mean for medical physicists and AAPM? John D. Hazle, Ph.D., FAAPM, FACR President-elect American Association of Physicists in Medicine Professor and Chairman
More informationAnalysis One Code Desc. Transaction Amount. Fiscal Period
Analysis One Code Desc Transaction Amount Fiscal Period 57.63 Oct-12 12.13 Oct-12-38.90 Oct-12-773.00 Oct-12-800.00 Oct-12-187.00 Oct-12-82.00 Oct-12-82.00 Oct-12-110.00 Oct-12-1115.25 Oct-12-71.00 Oct-12-41.00
More informationAT&T Global Network Client for Windows Product Support Matrix January 29, 2015
AT&T Global Network Client for Windows Product Support Matrix January 29, 2015 Product Support Matrix Following is the Product Support Matrix for the AT&T Global Network Client. See the AT&T Global Network
More informationPART 3.3: MicroRNA and Cancer
BIBM 2010 Tutorial: Epigenomics and Cancer PART 3.3: MicroRNA and Cancer Dec 18, 2010 Sun Kim at Indiana University Outline of Part 3.3 Background on microrna Role of microrna in cancer MicroRNA pathway
More informationCONTRACTING ORGANIZATION: University of Alabama at Birmingham Birmingham, AL 35294
AD Award Number: W81XWH-08-1-0030 TITLE: Regulation of Prostate Cancer Bone Metastasis by DKK1 PRINCIPAL INVESTIGATOR: Gregory A. Clines, M.D., Ph.D. CONTRACTING ORGANIZATION: University of Alabama at
More informationEarly detection of breast cancer
Early detection of breast cancer Professor Denise Kendrick Division of Primary Care 1 5/26/2016 Average Number of New Cases Per Year and Age-Specific Incidence Rates per 100,000 Population Females, UK
More informationTheories on Metastasis: Innovative Thinking An Advocacy Perspective
Theories on Metastasis: Innovative Thinking An Advocacy Perspective Project LEAD Workshop NBCC Annual Advocacy Conference 2011 Musa Mayer AdvancedBC.org 1 The Big Question If we want to end death from
More informationCOMPARISON OF FIXED & VARIABLE RATES (25 YEARS) CHARTERED BANK ADMINISTERED INTEREST RATES - PRIME BUSINESS*
COMPARISON OF FIXED & VARIABLE RATES (25 YEARS) 2 Fixed Rates Variable Rates FIXED RATES OF THE PAST 25 YEARS AVERAGE RESIDENTIAL MORTGAGE LENDING RATE - 5 YEAR* (Per cent) Year Jan Feb Mar Apr May Jun
More informationCOMPARISON OF FIXED & VARIABLE RATES (25 YEARS) CHARTERED BANK ADMINISTERED INTEREST RATES - PRIME BUSINESS*
COMPARISON OF FIXED & VARIABLE RATES (25 YEARS) 2 Fixed Rates Variable Rates FIXED RATES OF THE PAST 25 YEARS AVERAGE RESIDENTIAL MORTGAGE LENDING RATE - 5 YEAR* (Per cent) Year Jan Feb Mar Apr May Jun
More informationTypes of Cancers [-oma growth ]!
Cancer: disease of transcription factors and replication 1 Uncontrolled cell growth and division -> immortalized cells -> tumor growth -> metastasis (cells float away from tumor and spread throughout the
More informationTEXT PICTURE. Martin Puhr PhD. Medical University of Innsbruck. Department of Urology Division of Experimental Urology
TEXT PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer PICTURE Martin Puhr PhD Department of Urology
More informationCHAPTER 2: UNDERSTANDING CANCER
CHAPTER 2: UNDERSTANDING CANCER INTRODUCTION We are witnessing an era of great discovery in the field of cancer research. New insights into the causes and development of cancer are emerging. These discoveries
More informationFinancial Results. for FY 2010 ended March 2011. ~For healthy and affluent lives of people around the world~ http://www.transgenic.co.
Financial Results for FY 2010 ended March 2011 ~For healthy and affluent lives of people around the world~ http://www.transgenic.co.jp May 24, 2011 TRANS GENIC INC. Note: This material includes forward-looking
More informationThe TV Series. www.healthybodyhealthymind.com INFORMATION TELEVISION NETWORK
The TV Series www.healthybodyhealthymind.com Produced By: INFORMATION TELEVISION NETWORK ONE PARK PLACE 621 NW 53RD ST BOCA RATON, FL 33428 1-800-INFO-ITV www.itvisus.com 2005 Information Television Network.
More informationWntResearch. Foxy-5 A unique Phase 1 opportunity to combat the spreading of cancer
WntResearch Foxy-5 A unique Phase 1 opportunity to combat the spreading of cancer Why WntResearch is developing novel anti-cancer drugs Approximately 55 000 Swedish citizens are diagnosed with cancer every
More informationHow Cancer Begins???????? Chithra Manikandan Nov 2009
Cancer Cancer is one of the most common diseases in the developed world: 1 in 4 deaths are due to cancer 1 in 17 deaths are due to lung cancer Lung cancer is the most common cancer in men Breast cancer
More informationLESSON 3.5 WORKBOOK. How do cancer cells evolve? Workbook Lesson 3.5
LESSON 3.5 WORKBOOK How do cancer cells evolve? In this unit we have learned how normal cells can be transformed so that they stop behaving as part of a tissue community and become unresponsive to regulation.
More informationOBJECTIVES By the end of this segment, the community participant will be able to:
Cancer 101: Cancer Diagnosis and Staging Linda U. Krebs, RN, PhD, AOCN, FAAN OCEAN Native Navigators and the Cancer Continuum (NNACC) (NCMHD R24MD002811) Cancer 101: Diagnosis & Staging (Watanabe-Galloway
More informationTargeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
More informationCancer Research Experience Program. Opportunities for Howard University Students. 2016 Program Year
R O S W E L L PA R K C A N C E R I N S T I T U T E S Cancer Research Experience Program Opportunities for Howard University Students 2016 Program Year THE ROSWELL PARK/HOWARD UNIVERSITY CANCER SCHOLARS
More informationRegulation of Protein Translation and c-jun expression by Prostate Tumor Overexpressed1 (PTOV1)
Regulation of Protein Translation and c-jun expression by Prostate Tumor Overexpressed1 (PTOV1) Verónica Cánovas, PhD Student Laboratory of Cell Signalling and Cancer Progression, Dra. Rosanna Paciucci
More informationLEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials
LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials OUR FOCUS ABOUT emerging treatments Presentation for: Judith E. Karp, MD Advancements for Acute Myelogenous Leukemia Supported by an unrestricted educational
More informationCase 2:08-cv-02463-ABC-E Document 1-4 Filed 04/15/2008 Page 1 of 138. Exhibit 8
Case 2:08-cv-02463-ABC-E Document 1-4 Filed 04/15/2008 Page 1 of 138 Exhibit 8 Case 2:08-cv-02463-ABC-E Document 1-4 Filed 04/15/2008 Page 2 of 138 Domain Name: CELLULARVERISON.COM Updated Date: 12-dec-2007
More informationmicrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved
microrna 2 micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved Regulate gene expression by binding complementary regions at 3 regions of target mrnas Act as negative
More informationCancer SBL101. James Gomes School of Biological Sciences Indian Institute of Technology Delhi
Cancer SBL101 James Gomes School of Biological Sciences Indian Institute of Technology Delhi All Figures in this Lecture are taken from 1. Molecular biology of the cell / Bruce Alberts et al., 5th ed.
More informationGriffith University - Case for Support. Mesothelioma Research Program
Griffith University - Case for Support Mesothelioma Research Program Professor Lyn Griffiths Director, Dean, Research and Director, Genomics Research Centre (GHI) Established in 2007. Integrated health
More informationAdjuvant Therapy for Breast Cancer: Questions and Answers
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Adjuvant Therapy for Breast
More informationOctober is Breast Cancer Awareness Month!
October is Breast Cancer Awareness Month! A STUDY OF CHARACTERISTICS AND MANAGEMENT OF BREAST CANCER IN TAIWAN Eric Kam-Chuan Lau, OMS II a, Jim Yu, OMSII a, Christabel Moy, OMSII a, Jian Ming Chen, MD
More informationAchievements Report CURING CANCER. Of all the questions addressed to CPRIT, the toughest is: When are you going to find a cure for
Achievements Report August 2015 CURING CANCER Of all the questions addressed to CPRIT, the toughest is: When are you going to find a cure for cancer? Since cancer is complex and comes in many forms, its
More informationEnhanced Vessel Traffic Management System Booking Slots Available and Vessels Booked per Day From 12-JAN-2016 To 30-JUN-2017
From -JAN- To -JUN- -JAN- VIRP Page Period Period Period -JAN- 8 -JAN- 8 9 -JAN- 8 8 -JAN- -JAN- -JAN- 8-JAN- 9-JAN- -JAN- -JAN- -JAN- -JAN- -JAN- -JAN- -JAN- -JAN- 8-JAN- 9-JAN- -JAN- -JAN- -FEB- : days
More informationUpdate in Hematology Oncology Targeted Therapies. Mark Holguin
Update in Hematology Oncology Targeted Therapies Mark Holguin 25 years ago Why I chose oncology People How to help people with possibly the most difficult thing they may have to deal with Science Turning
More informationMetastatic breast cancer, HER2 overexpression, first-line therapy in combination with a taxane and trastuzumab
COMPENDIA TRANSPARENCY TRACKING FORM DRUG: Carboplatin INDICATION: Metastatic breast cancer, HER2 overexpression, first-line therapy in combination with a taxane and trastuzumab COMPENDIA TRANSPARENCY
More informationProgress and Prospects in Ovarian Cancer Screening and Prevention
Progress and Prospects in Ovarian Cancer Screening and Prevention Rebecca Stone, MD MS Assistant Professor Kelly Gynecologic Oncology Service The Johns Hopkins Hospital 1 No Disclosures 4/12/2016 2 Ovarian
More informationAn Update on Lung Cancer Diagnosis
An Update on Lung Cancer Diagnosis Dr Michael Fanning MBBS FRACGP FRACP RESPIRATORY AND SLEEP PHYSICIAN Mater Medical Centre Outline Risk factors for lung cancer Screening for lung cancer Radiologic follow-up
More informationModelling cell motion: From microscopic to macroscopic scale. Luigi Preziosi Luigi.preziosi@polito.it calvino.polito.it/~preziosi
Modelling cell motion: From microscopic to macroscopic scale Luigi Preziosi Luigi.preziosi@polito.it calvino.polito.it/~preziosi Modelling cell-ecm interaction: An opportunity to present different modelling
More informationUs TOO University Presents: Understanding Diagnostic Testing
Us TOO University Presents: Understanding Diagnostic Testing for Prostate Cancer Patients Today s speaker is Manish Bhandari, MD Program moderator is Pam Barrett, Us TOO International Made possible by
More informationTECHNICAL INSIGHTS TECHNOLOGY ALERT
TECHNICAL INSIGHTS TECHNOLOGY ALERT UNLOCKING BREAST CANCER TUMORS' DRUG RESISTANCE A troubling phenomenon in breast cancer treatment is that some patients tumors become resistant to treatments over time.
More informationTargeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma
The Use of Kinase Inhibitors: Translational Lab Results Targeting Specific Cell Signaling Pathways for the Treatment of Malignant Peritoneal Mesothelioma Sheelu Varghese, Ph.D. H. Richard Alexander, M.D.
More informationCancer and Massage. Metastasis?
Cancer and Massage Could Massage Therapy Promote CANCER Metastasis? This article provides new insights to this serious concern, which often has prevented affected patients from receiving massages. By Debra
More informationMedical Therapies Limited EGM Presentation
Medical Therapies Limited EGM Presentation Maria Halasz Chief Executive Officer 5 May 2009 1 Agenda 1. Company information 2. Recent developments 3. Business strategy 4. Key value inflection points for
More informationMetastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011
Metastatic Breast Cancer 201 Carolyn B. Hendricks, MD October 29, 2011 Overview Is rebiopsy necessary at the time of recurrence or progression of disease? How dose a very aggressive treatment upfront compare
More informationINTRODUCTION % Cells of Control % Cells of Control % Cells of Control A B Rapamycin 24 Hour 48 Hour MS-275 24 Hour 48 Hour 120.000 120.000 100.000 100.000 80.000 80.000 60.000 60.000 40.000 40.000
More information9. Discuss guidelines for follow-up post-thyroidectomy for cancer (labs/tests) HH
9. Discuss guidelines for follow-up post-thyroidectomy for cancer (labs/tests) HH Differentiated thyroid cancer expresses the TSH receptor on the cell membrane and responds to TSH stimulation by increasing
More informationNuevas tecnologías basadas en biomarcadores para oncología
Nuevas tecnologías basadas en biomarcadores para oncología Simposio ASEBIO 14 de marzo 2013, PCB Jose Jimeno, MD, PhD Co-Founder / Vice Chairman Pangaea Biotech SL Barcelona, Spain PANGAEA BIOTECH BUSINESS
More informationCellular, Molecular, and Biochemical Targets in Breast Cancer
Cellular, Molecular, and Biochemical Targets in Breast Cancer Kristy Kummerow Ingrid Meszoely December 12, 2012 VUMC Resident Bonus Conference One size fits all surgical treatment of breast cancer Wilhelm
More informationThe Biological Basis of Cancer. Annie Young, Professor of Nursing, University of Warwick, University Hospitals Coventry and Warwickshire
The Biological Basis of Cancer Annie Young, Professor of Nursing, University of Warwick, University Hospitals Coventry and Warwickshire Aim of Presentation By the end of this presentation you will: Be
More informationSMALL BUSINESS INNOVATION RESEARCH (SBIR) SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) GRANT APPLICATIONS
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES PHS 2015-2 OMNIBUS SOLICITATION OF THE NATIONAL INSTITUTES OF HEALTH, CENTERS FOR DISEASE CONTROL AND PREVENTION, FOOD AND DRUG ADMINISTRATION, AND ADMINISTRATION
More informationWhat is New in Oncology. Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals
What is New in Oncology Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals Personalized Medicine Personalized Genomics Genomic Medicine Precision Medicine Definition Application
More informationThe Nuts and Bolts of Multiple Sclerosis. Rebecca Milholland, M.D., Ph.D. Center for Neurosciences
The Nuts and Bolts of Multiple Sclerosis Rebecca Milholland, M.D., Ph.D. Center for Neurosciences Objectives Discuss which patients are at risk for Multiple Sclerosis Discuss the diagnostic criteria for
More informationMUTATION, DNA REPAIR AND CANCER
MUTATION, DNA REPAIR AND CANCER 1 Mutation A heritable change in the genetic material Essential to the continuity of life Source of variation for natural selection New mutations are more likely to be harmful
More informationFASEB Directory of Members Online
Head, Department of Anatomy and Radiology The College of Veterinary Medicine at the University of Georgia invites nominations and applications for the position of Head of the Department of Anatomy and
More informationState Annual Report Due Dates for Business Entities page 1 of 10
State Annual Report Due Dates for Business Entities page 1 of 10 If you form a formal business entity with the state, you may be required to file periodic reports on the status of your entity to preserve
More informationChing-Yao Yang, Yu-Wen Tien
Ching-Yao Yang, Yu-Wen Tien Division of General Surgery, Department of Surgery, National Taiwan University Hospital Oct-30-2010 Pancreatic NET have poorer prognosis when presence of liver metastases at
More information2015-16 BCOE Payroll Calendar. Monday Tuesday Wednesday Thursday Friday Jun 29 30 Jul 1 2 3. Full Force Calc
July 2015 CM Period 1501075 July 2015 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 August 2015 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26
More informationPrognostic and Predictive Factors in Oncology. Mustafa Benekli, M.D.
Prognostic and Predictive Factors in Oncology Mustafa Benekli, M.D. NCI Definitions ESMO Course -Essentials of Medical Oncology -Istanbul 2 Prognostic factor: NCI Definition A situation or condition, or
More informationGENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE
GENETIC PROFILES AND TARGETED TREATMENT OF CANCER - PERSONALIZED MEDICINE Branko Zakotnik MD, PhD Department of Medical Oncology Institute of Oncology Ljubljana 1 I have no conflict of interest to declare
More informationNo Disclosures. Learning Objectives 10/25/13
No Disclosures Gregory A. Brent, MD Departments of Medicine and Physiology David Geffen School of Medicine at UCLA VA Greater Los Angeles Healthcare System Learning Objectives Describe the pathways that
More informationFrequently Asked Questions About Ovarian Cancer
Media Contact: Gerri Gomez Howard Cell: 303-748-3933 gerri@gomezhowardgroup.com Frequently Asked Questions About Ovarian Cancer What is ovarian cancer? Ovarian cancer is a cancer that forms in tissues
More informationSAMO FoROMe Post-ESMO 2013 Breast Cancer
SAMO FoROMe Post-ESMO 2013 Breast Cancer Dr. med. Manuela Rabaglio Klinik und Poliklinik für Medizinische Onkologie Breast Cancer Track 300 Abstracts 142 Poster 11 Proffered paper 4 late breaking news
More informationCancer: DNA Synthesis, Mitosis, and Meiosis
Chapter 5 Cancer: DNA Synthesis, Mitosis, and Meiosis Copyright 2007 Pearson Copyright Prentice Hall, 2007 Inc. Pearson Prentice Hall, Inc. 1 What Is Cancer? Benign tumors do not invade surrounding tissue
More informationSimplifying Oncology Care
Simplifying Oncology Care March 2009 Research Philips Research focuses on ultrasound-mediated drug delivery Research Philips Research focuses on ultrasound-mediated drug delivery Philips Research and its
More informationhttp://www.univcan.ca/programs-services/international-programs/canadianqueen-elizabeth-ii-diamond-jubilee-scholarships/
QUANTITATIVE BIOLOGY AND MEDICAL GENETICS FOR THE WORLD PROGRAM ANNOUNCEMENT The "Quantitative Biology and Medical Genetics for the World" program at McGill is offering a number of prestigious Queen Elizabeth
More informationAppendix One. HER2-positive early breast cancer, its treatment and prognosis
Appendix One. HER2-positive early breast cancer, its treatment and prognosis Breast cancer and HER2/neu over-expression Health need is one of PHARMAC s nine decision criteria (http://www.pharmac.govt.nz/pdf/231205.pdf
More informationCancer: Cells Behaving Badly
Cancer: Cells behaving badly It s quite likely your body is harboring precancerous cells. Don t panic: this doesn t mean you have cancer. Many of us have cells here and there with defense mechanisms that
More informationNew strategies in anticancer therapy
癌 症 診 療 指 引 簡 介 及 臨 床 應 用 New strategies in anticancer therapy 中 山 醫 學 大 學 附 設 醫 院 腫 瘤 內 科 蔡 明 宏 醫 師 2014/3/29 Anti-Cancer Therapy Surgical Treatment Radiotherapy Chemotherapy Target Therapy Supportive
More informationBreast Imaging Made Brief and Simple. Jane Clayton MD Associate Professor Department of Radiology LSUHSC New Orleans, LA
Breast Imaging Made Brief and Simple Jane Clayton MD Associate Professor Department of Radiology LSUHSC New Orleans, LA What women are referred for breast imaging? Two groups of women are referred for
More informationOur body is a community of
Fundamental Understandings Tumor cells roam the body by evading the controls that keep normal cells in place. That fact offers clues to fighting cancer by Erkki Ruoslahti Our body is a community of cells,
More informationCancer Immunotherapy: Can Your Immune System Cure Cancer? Steve Emerson, MD, PhD Herbert Irving Comprehensive Cancer Center
Cancer Immunotherapy: Can Your Immune System Cure Cancer? Steve Emerson, MD, PhD Herbert Irving Comprehensive Cancer Center Bodnar s Law Simple Things are Important Very Simple Things are Very Important
More informationKidney Cancer OVERVIEW
Kidney Cancer OVERVIEW Kidney cancer is the third most common genitourinary cancer in adults. There are approximately 54,000 new cancer cases each year in the United States, and the incidence of kidney
More informationCase of the. Month October, 2012
Case of the Month October, 2012 Case The patient is a 47-year-old male with a 3-week history of abdominal pain. A CT scan of the abdomen revealed a suggestion of wall thickening at the tip of the appendix
More information2006 7.012 Problem Set 6 KEY
2006 7.012 Problem Set 6 KEY ** Due before 5 PM on WEDNESDAY, November 22, 2006. ** Turn answers in to the box outside of 68-120. PLEASE WRITE YOUR ANSWERS ON THIS PRINTOUT. 1. You create an artificial
More informationLCFA/IASLC LORI MONROE SCHOLARSHIP IN TRANSLATIONAL LUNG CANCER RESEARCH
LCFA/IASLC LORI MONROE SCHOLARSHIP IN TRANSLATIONAL LUNG CANCER RESEARCH FUNDING OPPORTUNITY DESCRIPTION 2016 REQUEST FOR APPLICATION (RFA) Lung Cancer Foundation of America (LCFA) and the International
More informationRisk Management. Best Practices. ERP System Implementation Challenges and Risks
Risk Management Best Practices ERP System Implementation Challenges and Risks January 7, 2010 Agenda Introductions Mark Nadolny (5 min) Solution Implementation Overview David Dominguez (10 min) Impact
More informationYour Immune System & Cancer Treatment
Your Immune System & Cancer Treatment Immunotherapy Today, immunotherapy is one of the most exciting areas of new discoveries and treatments for many different kinds of cancer. Researchers now know that
More informationThe Huntington Library, Art Collections, and Botanical Gardens
The Huntington Library, Art Collections, and Botanical Gardens Do Plants Get Cancer? The Effects of Infecting Sunflower Seedlings with Agrobacterium tumefaciens Overview Students infect sunflowers with
More informationChapter 8. Summary and Perspectives
Chapter 8 Summary and Perspectives 131 Chapter 8 Summary Overexpression of the multidrug resistance protein MRP1 confer multidrug resistance (MDR) to cancer cells. The contents of this thesis describe
More informationReport with statistical data from 2007
2008 Cancer Program Annual Report with statistical data from 2007 Lake Cumberland Regional Hospital 305 Langdon Streett Somerset, KY 42503 Telephone: 606-679-7441 Fax: 606-678-9919 Cancer Committee Mullai,
More informationCENTERPOINT ENERGY TEXARKANA SERVICE AREA GAS SUPPLY RATE (GSR) JULY 2015. Small Commercial Service (SCS-1) GSR
JULY 2015 Area (RS-1) GSR GSR (LCS-1) Texarkana Incorporated July-15 $0.50690/Ccf $0.45450/Ccf $0.00000/Ccf $2.85090/MMBtu $17.52070/MMBtu Texarkana Unincorporated July-15 $0.56370/Ccf $0.26110/Ccf $1.66900/Ccf
More informationProgramme. Michele Grieco Dipartimento di Scienze Ambientali Seconda Università degli Studi di Napoli Naples, Italy
Programme Invited Speakers: Reuven Agami (The Netherlands), Manuela Baccarini (Austria), Allan Balmain (USA), Daniel Birnbaum (France), Anne-Lise Børresen-Dale (Norway), Carlos Caldas (UK), Silvana Canevari
More informationAmerican Cancer Society Extramural Grants
Page: 1 Cancer Control Career Development Award for Primary Care Physicians (CCCDA) CCCDA-14-013-01 Cole, ison M., MD MENTOR: Baldwin, Laura-Mae, MD, MPH Department of Family Medicine Improving Colorectal
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationEpidemiology, Staging and Treatment of Lung Cancer. Mark A. Socinski, MD
Epidemiology, Staging and Treatment of Lung Cancer Mark A. Socinski, MD Associate Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive Cancer Center University of
More informationFulfilling the Promise
Fulfilling the Promise Advancing the Fight Against Cancer: America s Medical Schools and Teaching Hospitals For more than a century, the nation s medical schools and teaching hospitals have worked to understand,
More informationBiofocus Molecular Diagnostic Panel
Biofocus Molecular Diagnostic Panel Dr. Lothar Prix Biofocus GmbH, Recklinghausen, Germany www.biofocus.de Molecular detection of infectious diseases Human & veterinary hereditary diseases / genetic predisposition
More informationChallenges in gastric, appendiceal and rectal NETs Leuven, 29.11.2014
Challenges in gastric, appendiceal and rectal NETs Leuven, 29.11.2014 Prof. Dr. Chris Verslype, Leuven Prof. Dr. Aurel Perren, Bern Menue Challenges: 1. Gastric NET 2. Appendiceal NET 3. Rectal NET SEER,
More informationNEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA)
NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA) Merat Esfahani, MD Medical Oncologist, Hematologist Cancer Liaison Physician SwedishAmerican Regional Cancer Center
More informationBottlenecks in Clinical Source Material Acquisition. Aby J. Mathew, PhD May 5, 2009 ISCT Annual Meeting San Diego, CA amathew@biolifesolutions.
Bottlenecks in Clinical Source Material Acquisition Aby J. Mathew, PhD May 5, 2009 ISCT Annual Meeting San Diego, CA amathew@biolifesolutions.com Biopreservation What s the issue? Biopreservation considerations
More informationREWRITING PAYER/PROVIDER COLLABORATION July 24, 2015. MIKE FAY Vice President, Health Networks
REWRITING PAYER/PROVIDER COLLABORATION July 24, 2015 MIKE FAY Vice President, Health Networks AGENDA ACO Overview ACO Financial Performance ACO Quality Performance Observations 2 AGENDA ACO OVERVIEW ACO
More informationGrade 4 Thrombocytopenia During. Predictor of Response in Melanoma but Not in Renal Cell Cancer.
Grade 4 Thrombocytopenia During Treatment with High-Dose IL-2 2 (HD IL-2) is a Predictor of Response in Melanoma but Not in Renal Cell Cancer. Timothy E. Bael, M.D. Bercedis L. Peterson, Ph.D. Karima Rasheed,
More informationAshley Institute of Training Schedule of VET Tuition Fees 2015
Ashley Institute of Training Schedule of VET Fees Year of Study Group ID:DECE15G1 Total Course Fees $ 12,000 29-Aug- 17-Oct- 50 14-Sep- 0.167 blended various $2,000 CHC02 Best practice 24-Oct- 12-Dec-
More informationRecommendations on Disease Management for Patients with Advanced HER2-Positive Breast Cancer and Brain Metastases
Recommendations on Disease Management for Patients with Advanced HER2-Positive Breast Cancer and Brain Metastases Clinical Practice Guideline www.asco.org/guidelines/her2brainmets American Society of Clinical
More informationComparing Immunotherapy with High Dose IL-2 and Ipilimumab
Comparing Immunotherapy with High Dose IL-2 and Ipilimumab Michael K Wong MD PhD FRCPC mike.wong@med.usc.edu Disclosures Speaker s Bureau, Advisory Boards, Consultant: Prometheus Bristol Myers Squibb Novartis
More informationContents. molecular biology techniques. - Mutations in Factor II. - Mutations in MTHFR gene. - Breast cencer genes. - p53 and breast cancer
Contents Introduction: biology and medicine, two separated compartments What we need to know: - boring basics in DNA/RNA structure and overview of particular aspects of molecular biology techniques - How
More informationBiomarker Trends in Breast Cancer Research
WHITE PAPER Biomarker Trends in Breast Cancer Research Jason Hill, PhD, Associate Director, External Science Affairs, Quintiles Quintiles examines the novel drug combinations and mechanisms of action that
More informationMetastatic breast cancer represents an incurable condition associated with an average survival time of 18 to 24 months.
TACT-2C Trial A phase II randomized, open-label study evaluating the addiction of trastuzumabto (nabtm)-paclitaxel as first line treatment in primary HER2 negative metastatic breast cancer patients with
More informationWhen it comes to treating breast cancer, doing less does more October is Breast Cancer Awareness Month
For Immediate Release Oct. 8, 2012 When it comes to treating breast cancer, doing less does more October is Breast Cancer Awareness Month SEATTLE Oncologists and researchers are discovering that when it
More informationMalignant Mesothelioma - Pipeline Review, H2 2014
Brochure More information from http://www.researchandmarkets.com/reports/2888197/ Malignant Mesothelioma - Pipeline Review, H2 2014 Description: Malignant Mesothelioma - Pipeline Review, H2 2014 Summary
More informationImplementation Date: April 2015 Clinical Operations
National Imaging Associates, Inc. Clinical guideline PROSTATE CANCER Original Date: March 2011 Page 1 of 5 Radiation Oncology Last Review Date: March 2015 Guideline Number: NIA_CG_124 Last Revised Date:
More information